CleanCure™ bioinks are currently in a prototype phase and are not yet commercially available.

We are inviting selected partners to join our pilot program and become early users, contributing to the final development of the technology.
If you would like to be among the first, get in touch with us.

How the CleanCure™ Platform Works

The CleanCure™ platform is based on a modular material design that enables precise control over photochemical crosslinking and final biomaterial performance. The CM3X component serves as the active module responsible for absorbing light at 365 nm and initiating a [2+2] photocycloaddition reaction without the need for a photoinitiator. This mechanism enables a cleaner crosslinking process, improving biocompatibility and reducing cytotoxicity risks associated with conventional photoinitiators. The hybrid module (VBX / CM6X / PNX / CYX) determines how the absorbed energy is translated into network formation kinetics and the final mechanical performance of the material. By modulating crosslinking dynamics and structural organization, the hybrid components enable precise tuning of elasticity, stiffness, and stability. This modular architecture allows for the rational selection of materials tailored to the intended tissue reconstruction type and specific process requirements.